285
Views
14
CrossRef citations to date
0
Altmetric
Original Research

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis

ORCID Icon, , , , , , & ORCID Icon show all
Pages 153-161 | Published online: 12 Feb 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Jia C Gao, Albert G Wu, Marissa N Contento, Jacqueline M Maher & Abigail Cline. (2022) Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis. Clinical, Cosmetic and Investigational Dermatology 15, pages 395-402.
Read now
Clara De Simone, Maria Concetta Fargnoli, Paolo Amerio, Luca Bianchi, Maria Esposito, Federico Pirro, Concetta Potenza, Federica Ricceri, Franco Rongioletti, Luca Stingeni & Francesca Prignano. (2021) Risk of infections in psoriasis: assessment and challenges in daily management. Expert Review of Clinical Immunology 17:11, pages 1211-1220.
Read now

Articles from other publishers (12)

Shingo Konno, Takafumi Uchi, Jun Isonishi, Mari Matsushima, Hideo Kihara, Hideki Sugimoto & Toshiki Fujioka. (2022) Development of infections among patients with myasthenia gravis undergoing immunotherapy. Clinical and Experimental Neuroimmunology 14:1, pages 34-43.
Crossref
Katarzyna Korecka, Anna Wiśniewska‐Szymańska & Dominik Mikiel. (2022) The impact of systemic psoriasis treatments on human papillomavirus activation and propagation. Australasian Journal of Dermatology 63:3, pages 293-302.
Crossref
Alfonso Motolese, Manuela Ceccarelli, Laura Macca, Federica Li Pomi, Ylenia Ingrasciotta, Giuseppe Nunnari & Claudio Guarneri. (2022) Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomedicines 10:2, pages 228.
Crossref
Hsien-Yi Chiu, Yi-Teng Hung, Shi-Wei Huang & Yu-Huei Huang. (2022) Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis. Therapeutic Advances in Chronic Disease 13, pages 204062232210911.
Crossref
Matheus Vieira, Mathieu Vautier, Frédéric Charlotte & David Saadoun. (2021) Mycobacterium bovis infection under apremilast in Behçet's syndrome . Rheumatology 60:9, pages e301-e303.
Crossref
M. M. Baranova, N. V. Muravyeva & B. S. Belov. (2021) The frequency and structure of comorbid infections in patients with spondyloarthritis (preliminary own data). Meditsinskiy sovet = Medical Council:2, pages 122-126.
Crossref
Andrea Picchianti-Diamanti, Francesca Romana Spinelli, Maria Manuela Rosado, Fabrizio Conti & Bruno Laganà. (2021) Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases. International Journal of Molecular Sciences 22:5, pages 2638.
Crossref
Matheus Vieira, Solène Buffier, Mathieu Vautier, Alexandre Le Joncour, Yvan Jamilloux, Mathieu Gerfaud-Valentin, Laurence Bouillet, Estibaliz Lazaro, Stéphane Barete, Laurent Misery, Delphine Gobert, Tiphaine Goulenok, Olivier Fain, Karim Sacre, Pascal Sève, Patrice Cacoub, Cloé Comarmond & David Saadoun. (2021) Apremilast in Refractory Behçet’s Syndrome: A Multicenter Observational Study. Frontiers in Immunology 11.
Crossref
Olivier Lortholary, Mario Fernandez-Ruiz, John W Baddley, Oriol Manuel, Xavier Mariette & Kevin L Winthrop. (2020) Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Annals of the Rheumatic Diseases 79:12, pages 1532-1543.
Crossref
N. V. Muravyeva, B. S. Belov, M. M. Baranova & T. V. Korotaeva. (2020) Comorbid infections in spondyloarthritis: a modern view of the problem. Modern Rheumatology Journal 14:4, pages 103-110.
Crossref
B. S. Belov, N. V. Muravyova, M. M. Baranova & T. V. Korotaeva. (2020) Problem of comorbid infections in patients with psoriatic arthritis. Medical alphabet:15 (2020), pages 22-28.
Crossref
Susana Armesto, Carmen González Vela & Marco Antonio González López. (2020) Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID‐19 era. Dermatologic Therapy 33:4.
Crossref